Lower CSF amyloid beta peptides and higher F2-isoprostanes in cognitively intact elderly individuals with major depressive disorder
about
Is there Progress? An Overview of Selecting Biomarker Candidates for Major Depressive Disorderγ-secretase binding sites in aged and Alzheimer's disease human cerebrum: the choroid plexus as a putative origin of CSF AβDysregulation of leukocyte gene expression in women with medication-refractory depression versus healthy non-depressed controls.Relationship between cyclophilin a levels and matrix metalloproteinase 9 activity in cerebrospinal fluid of cognitively normal apolipoprotein e4 carriers and blood-brain barrier breakdownIncreased levels of ascorbic acid in the cerebrospinal fluid of cognitively intact elderly patients with major depression: a preliminary study.Soluble amyloid-β levels and late-life depressionSubjective cognitive concerns and neuropsychiatric predictors of progression to the early clinical stages of Alzheimer disease.Influence of lifestyle modifications on age-related free radical injury to brain.Depressive Symptoms in Clinical and Incipient Alzheimer's Disease.Reduced cerebrospinal fluid levels of brain-derived neurotrophic factor is associated with cognitive impairment in late-life major depression.Increased risk of affective disorders in type 2 diabetes is minimized by sulfonylurea and metformin combination: a population-based cohort studyA Meta-Analysis of Oxidative Stress Markers in Depression.Depressive symptoms are more strongly related to executive functioning and episodic memory among African American compared with non-Hispanic White older adultsLipid peroxidation and depressed mood in community-dwelling older men and women."Noncognitive" symptoms of early Alzheimer disease: a longitudinal analysis.A study on the specificity of the association between hippocampal volume and delayed primacy performance in cognitively intact elderly individualsPlasma biosignature and brain pathology related to persistent cognitive impairment in late-life depression.Depressive Symptoms and Biomarkers of Alzheimer's Disease in Cognitively Normal Older Adults.Output order and variability in free recall are linked to cognitive ability and hippocampal volume in elderly individuals.Altered concentrations of amyloid precursor protein metabolites in the cerebrospinal fluid of patients with bipolar disorderAmyloid Hypothesis: Is There a Role for Antiamyloid Treatment in Late-Life Depression?Amyloid-associated depression and ApoE4 allele: longitudinal follow-up for the development of Alzheimer's disease.Abnormality in glutamine-glutamate cycle in the cerebrospinal fluid of cognitively intact elderly individuals with major depressive disorder: a 3-year follow-up study.CSF biomarkers of Alzheimer disease: "noncognitive" outcomes.Plasma and cerebrospinal fluid amyloid-β levels in late-life depression: A systematic review and meta-analysis.Non-Alzheimer's disease-related memory impairment and dementia.Classifying oxidative stress by F2-isoprostane levels across human diseases: A meta-analysis.Neurodegeneration, β-amyloid and mood disorders: state of the art and future perspectives.Current understanding of the neurobiology and longitudinal course of geriatric depression.Amyloid-beta and depression in healthy older adults: a systematic review.Depressive Symptoms and Tau Accumulation in the Inferior Temporal Lobe and Entorhinal Cortex in Cognitively Normal Older Adults: A Pilot Study.State-dependent alterations in cerebrospinal fluid Aβ42 levels in cognitively intact elderly with late-life major depression.Hippocampal volume and integrity as predictors of cognitive decline in intact elderly.The recency ratio is associated with reduced CSF glutamate in late-life depression.Tau in Late-Life Depression: A Systematic Review and Meta-Analysis.High amyloid-β deposition related to depressive symptoms in older individuals with normal cognition: a pilot study.Lack of a Role for Alzheimer's Disease Pathology in Late-Life Depression, or Just No Relationship With Amyloid?The relationship between CSF tau markers, hippocampal volume and delayed primacy performance in cognitively intact elderly individuals.CSF neurofilament light concentration is increased in presymptomatic CHMP2B mutation carriers.Mechanism of depression as a risk factor in the development of Alzheimer's disease: the function of AQP4 and the glymphatic system.
P2860
Q26747511-C0213149-5E49-4A1A-B550-CDEDE10E63F2Q28687678-6DDB9295-A9CF-4F1F-93C0-A1C36CC0E555Q33588628-B4C1BEA7-1B1F-44F5-BF04-27906B77A484Q33717021-CC108FB1-2638-4BB1-A17C-D68619A20845Q33799643-4AE52633-AE5C-4DC7-8F92-1004DADA601CQ33933220-582BC896-6356-4CC3-86D5-FB34F86C7FC7Q34090664-350BAC58-FBD6-4C02-8AF2-6B5F8DBC1A63Q34160762-27B35A75-E3FB-4279-A644-DD5074163160Q34163446-924C0E8E-7A2F-4FE2-BE82-D14C25913847Q34442861-FA7ABD68-FBB1-47C0-950A-477EB1464927Q34495632-2127D4DB-499F-4907-8F6C-6A1AE50A51E8Q34497237-6349AA29-CB5C-48FE-9F12-DE8DFCEF4DB1Q34683644-7E3BAE0C-1FA6-4AB7-AD61-609B367FE967Q34775703-4037C8A2-5D66-4C76-B5FC-4D12355B453BQ35106233-73BB79A8-5559-4CBD-B94D-4859B3273567Q35132457-CED09BC0-40F1-442D-A24B-C8DCB7DE4C01Q35828096-D1B240F9-A782-423F-AF2C-ADAFFDC2FC43Q35981455-D277B6DA-1703-4CD5-90F9-72E6CC4B0D56Q36421753-98771142-9D22-4C72-B596-F5961D62FBFDQ36610063-5FB8F8EF-1AFA-424A-A7E6-AD1B66568FE7Q36711795-539A69DE-E19B-463E-94B3-369F8D482D70Q36825209-3B4B5DE0-6467-43E5-AA4C-486A927BF627Q36915565-9D1780EC-E550-4C40-8421-6B17F5C478F9Q37372440-17DF1160-B80D-4B94-B5C6-3BD5B27559B1Q37403796-D52AA0FF-FF26-48B6-A573-2C5BAFD9CAFDQ37503811-ABBA767D-6ECD-44D0-A26F-0A6A4FF91981Q37741459-ED3B68FF-C09C-45E3-972A-123A2F51993BQ38045223-7E811915-CA90-4122-99B5-655432E12608Q38229434-C2BA1B45-FD71-4C62-9AE6-7A7A6C531859Q38270148-212EBB1E-61F8-4E5A-B043-D7ADD1F9752AQ38659171-5D6B4321-3266-4727-B9D9-06E0F9A0108EQ38832712-F87229F2-D156-411D-8669-B6EFBEB500FBQ38852655-722F1D9B-C8BC-4CC8-9EA4-2D34924FCEE0Q38890806-EE054A79-3CB1-4DB7-85E1-66B073FD6E4FQ38920533-D91C3714-3247-4B04-BD3E-E427EE72DB5DQ38920888-102342E5-58B9-4919-8B51-00CFC070C4CFQ42255136-35466A5D-4877-47BC-8170-B56A5FF892FDQ42423876-F8CF38A6-09F0-4F3B-B1C1-B9A987393CAEQ47315423-4B7C8A45-EC88-4BD1-8D66-E3803E6F2F42Q47597733-90BD0A05-C6D9-4A6E-8640-B21FE78DD86A
P2860
Lower CSF amyloid beta peptides and higher F2-isoprostanes in cognitively intact elderly individuals with major depressive disorder
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Lower CSF amyloid beta peptide ...... with major depressive disorder
@ast
Lower CSF amyloid beta peptide ...... with major depressive disorder
@en
type
label
Lower CSF amyloid beta peptide ...... with major depressive disorder
@ast
Lower CSF amyloid beta peptide ...... with major depressive disorder
@en
prefLabel
Lower CSF amyloid beta peptide ...... with major depressive disorder
@ast
Lower CSF amyloid beta peptide ...... with major depressive disorder
@en
P2093
P2860
P50
P1476
Lower CSF amyloid beta peptide ...... with major depressive disorder
@en
P2093
Antero S Sarreal
Domenico Pratico
Pankaj D Mehta
Raymundo T Hernando
P2860
P304
P356
10.1176/APPI.AJP.2011.11081153
P407
P50
P577
2012-05-01T00:00:00Z